These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10864369)

  • 1. Role of estrogens in human benign prostatic hyperplasia.
    Sciarra F; Toscano V
    Arch Androl; 2000; 44(3):213-20. PubMed ID: 10864369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen and androgen signaling in the pathogenesis of BPH.
    Ho CK; Habib FK
    Nat Rev Urol; 2011 Jan; 8(1):29-41. PubMed ID: 21228820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Physiopathological aspects of the treatment of benign prostatic hypertrophy. Role of prostatic stroma and estrogens].
    Solè-Balcells F
    J Urol (Paris); 1993; 99(6):303-6. PubMed ID: 7516373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a new steroidal aromatase inhibitor, TZA-2237, and/or chlormadinone acetate on hormone-induced and spontaneous canine benign prostatic hyperplasia.
    Ito K; Fukabori Y; Shibata Y; Suzuki K; Mieda M; Gotanda K; Honma S; Yamanaka H
    Eur J Endocrinol; 2000 Oct; 143(4):543-54. PubMed ID: 11022202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia.
    Levine AC; Kirschenbaum A; Gabrilove JL
    Mt Sinai J Med; 1997 Jan; 64(1):20-5. PubMed ID: 8997072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group.
    Radlmaier A; Eickenberg HU; Fletcher MS; Fourcade RO; Reis Santos JM; van Aubel OG; Bono AV
    Prostate; 1996 Oct; 29(4):199-208. PubMed ID: 8876703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bakuchiol suppresses oestrogen/testosterone-induced Benign Prostatic Hyperplasia development through up-regulation of epithelial estrogen receptor β and down-regulation of stromal aromatase.
    Miao L; Jiao C; Shao R; Qi Y; Fan G; Li X; Wang Y; Zhu Y; Zhang J; Gao X
    Toxicol Appl Pharmacol; 2019 Oct; 381():114637. PubMed ID: 31238046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgens and estrogens in benign prostatic hyperplasia: past, present and future.
    Nicholson TM; Ricke WA
    Differentiation; 2011; 82(4-5):184-99. PubMed ID: 21620560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and experimental studies of benign prostatic hyperplasia.
    Coffey DS; Walsh PC
    Urol Clin North Am; 1990 Aug; 17(3):461-75. PubMed ID: 1695775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role of tissue steroids in benign hyperplasia and prostate cancer].
    Voigt KD; Bartsch W
    Urologe A; 1987 Nov; 26(6):349-57. PubMed ID: 2448941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of aging on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate.
    Krieg M; Nass R; Tunn S
    J Clin Endocrinol Metab; 1993 Aug; 77(2):375-81. PubMed ID: 7688377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atamestane: an aromatase inhibitor for the treatment of benign prostatic hyperplasia. A short review.
    el Etreby MF
    J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):565-72. PubMed ID: 7682838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate.
    Krieg M; Bartsch W; Thomsen M; Voigt KD
    J Steroid Biochem; 1983 Jul; 19(1A):155-61. PubMed ID: 6193338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of estrogen deprivation on human benign prostatic hyperplasia.
    Schweikert HU; Tunn UW; Habenicht UF; Arnold J; Senge T; Schulze H; Schröder FH; Blom JH; Ennemoser O; Horniger W
    J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):573-6. PubMed ID: 7682839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors.
    Habenicht UF; Tunn UW; Senge T; Schröder FH; Schweikert HU; Bartsch G; el Etreby MF
    J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):557-63. PubMed ID: 7682837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies.
    Habenicht UF; el Etreby MF
    J Androl; 1991; 12(6):395-402. PubMed ID: 1722796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogens and benign prostatic hyperplasia: the basis for aromatase inhibitor therapy.
    Henderson D; Habenicht UF; Nishino Y; el Etreby MF
    Steroids; 1987; 50(1-3):219-33. PubMed ID: 2460976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone concentration, metabolic disorders and immunoexpression of androgen and estrogen-alpha receptors in men with benign prostatic hyperplasia and testosterone deficiency syndrome.
    Ryl A; Rotter I; Slojewski M; Dolegowska B; Grabowska M; Baranowska-Bosiacka I; Laszczynska M
    Folia Histochem Cytobiol; 2015; 53(3):227-35. PubMed ID: 26400665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgens and estrogens in the plasma and prostatic tissue of normal dogs and dogs with benign prostatic hypertrophy.
    Lloyd JW; Thomas JA; Mawhinney MG
    Invest Urol; 1975 Nov; 13(3):220-22. PubMed ID: 53217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine treatment of benign prostatic hypertrophy: current concepts.
    Matzkin H; Braf Z
    Urology; 1991 Jan; 37(1):1-16. PubMed ID: 1702565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.